Literature DB >> 19995568

Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia.

Chantal Schlumberger1, Małgorzata Pietraszek, Andreas Gravius, Wojciech Danysz.   

Abstract

Metabotropic glutamate receptors of the subtype 5 (mGluR(5)) are located in brain regions implicated in schizophrenia such as the cerebral cortex or the nucleus accumbens. They may therefore provide an interesting target for the treatment of psychoses. Currently available agonists of mGluR(5) are not selective, do not penetrate the brain and induce a tonic activation resulting in a rapid desensitization. Therefore, the research focus was shifted to positive allosteric modulators (PAMs). Subsequently several mGluR(5) PAMs have been discovered, e.g. ADX47273 (S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone). In the present study, effects of ADX47273 (1-100mg/kg) were evaluated in rat models used for detecting antipsychotic-like activity: the conditioned avoidance response (CAR) and the phencyclidine (PCP)-induced hyperlocomotion models. Furthermore, the cataleptogenic potential of ADX47273 was compared to that of haloperidol. ADX47273 (100mg/kg) and various clinically used neuroleptics (haloperidol, olanzapine, and aripiprazole) attenuated CAR behaviour in rats. However, ADX47273 and aripiprazole failed to reduce the PCP-induced hyperlocomotion, whereas olanzapine and haloperidol diminished it. In contrast to haloperidol, ADX47273 (100mg/kg) failed to induce consistent catalepsy in rats. In conclusion, ADX47273 shows promising antipsychotic activity in some tests which require future investigation. (c) 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19995568     DOI: 10.1016/j.pbb.2009.12.002

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  18 in total

Review 1.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

2.  The mGluR5 Positive Allosteric Modulator CDPPB Does Not Alter Extinction or Contextual Reinstatement of Methamphetamine-Seeking Behavior in Rats.

Authors:  John J Widholm; Justin T Gass; Richard M Cleva; M Foster Olive
Journal:  J Addict Res Ther       Date:  2011-12-24

Review 3.  Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).

Authors:  Shaun R Stauffer
Journal:  ACS Chem Neurosci       Date:  2011-06-27       Impact factor: 4.418

Review 4.  Newer antipsychotics and upcoming molecules for schizophrenia.

Authors:  Melvin George; Radhika Amrutheshwar; Ravi Philip Rajkumar; Shivanand Kattimani; Steven Aibor Dkhar
Journal:  Eur J Clin Pharmacol       Date:  2013-04-02       Impact factor: 2.953

5.  Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).

Authors:  María Luz Martín-Martín; José Manuel Bartolomé-Nebreda; Susana Conde-Ceide; Sergio A Alonso de Diego; Silvia López; Carlos M Martínez-Viturro; Han Min Tong; Hilde Lavreysen; Gregor J Macdonald; Thomas Steckler; Claire Mackie; Thomas M Bridges; J Scott Daniels; Colleen M Niswender; Meredith J Noetzel; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer
Journal:  Bioorg Med Chem Lett       Date:  2015-01-28       Impact factor: 2.823

Review 6.  Metabotropic glutamate receptors as therapeutic targets for schizophrenia.

Authors:  Paige N Vinson; P Jeffrey Conn
Journal:  Neuropharmacology       Date:  2011-05-19       Impact factor: 5.250

Review 7.  Development of allosteric modulators of GPCRs for treatment of CNS disorders.

Authors:  Hilary Highfield Nickols; P Jeffrey Conn
Journal:  Neurobiol Dis       Date:  2013-09-27       Impact factor: 5.996

8.  NMDA receptor hypofunction phase couples independent γ-oscillations in the rat visual cortex.

Authors:  Himashi Anver; Peter D Ward; Andor Magony; Martin Vreugdenhil
Journal:  Neuropsychopharmacology       Date:  2010-10-20       Impact factor: 7.853

9.  N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.

Authors:  K J Gregory; E J Herman; A J Ramsey; A S Hammond; N E Byun; S R Stauffer; J T Manka; S Jadhav; T M Bridges; C D Weaver; C M Niswender; T Steckler; W H Drinkenburg; A Ahnaou; H Lavreysen; G J Macdonald; J M Bartolomé; C Mackie; B J Hrupka; M G Caron; T L Daigle; C W Lindsley; P J Conn; C K Jones
Journal:  J Pharmacol Exp Ther       Date:  2013-08-21       Impact factor: 4.030

10.  Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine.

Authors:  Nicholas E Clifton; Nadège Morisot; Sylvie Girardon; Mark J Millan; Florence Loiseau
Journal:  Psychopharmacology (Berl)       Date:  2012-09-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.